- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
FDA placed clinical hold on Biomx's Phase 2b trial.
3 reports, 1 independent
Updated Aug 19
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA placed clinical hold on Biomx's Phase 2b trial.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA placed a clinical hold on Biomx's Phase 2b trial.1 source
Biomx uses the BOLT platform and is based in Israel.1 source
FDA is reviewing trial plans for BiomX.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- Matricelf Ltd. is seeking feedback from the FDA regarding its clinical trial design. The company is currently listed on the Tel Aviv Stock Exchange with plans for a dual listing to support its transition.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- Cardiff Oncology and Nerviano Medical Sciences are seeking FDA regulatory review for Phase 3 trials and managing a licensing dispute over onvansertib.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA approval enables commercial availability for a product associated with Indianapolis.
Coverage
Newest first; wire copies grouped- GlobeNewswireBiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on thi
- GlobeNewswireBiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025 NESS ZIONA, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Co
- GlobeNewswireBiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis First patient dosing in Company’s Phase 2b trial marks pivotal miles